Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Oncogene
|
August 30, 2000
The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner
N Ekman, E Arighi, I Rajantie, et al.
The Journal of Biological Chemistry
|
April 18, 1998
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities
V Joukov, V Kumar, T Sorsa, et al.
The EMBO Journal
|
February 21, 1998
Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation
J Klefstrom, E Arighi, T Littlewood, et al.
Molecular and Cellular Biology
|
June 21, 2001
Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium
I Rajantie, N Ekman, K Iljin, et al.
Oncogene
|
June 1, 1994
The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins
M G Borrello, G Pelicci, E Arighi, et al.
Molecular and Cellular Biology
|
January 1, 1993
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A
I Bongarzone, N Monzini, M G Borrello, et al.
Nature Genetics
|
May 1, 1995
Loss of function effect of RET mutations causing Hirschsprung disease
B Pasini, M G Borrello, A Greco, et al.
Oncogene
|
December 7, 1995
RET activation by germline MEN2A and MEN2B mutations
M G Borrello, D P Smith, B Pasini, et al.
Oncogene
|
June 29, 2001
Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein
E Mercalli, S Ghizzoni, E Arighi, et al.
Oncogene
|
February 20, 1997
Identification of Shc docking site on Ret tyrosine kinase
E Arighi, L Alberti, F Torriti, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Oncogene
|
August 30, 2000
The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner
N Ekman, E Arighi, I Rajantie, et al.
The Journal of Biological Chemistry
|
April 18, 1998
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities
V Joukov, V Kumar, T Sorsa, et al.
The EMBO Journal
|
February 21, 1998
Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation
J Klefstrom, E Arighi, T Littlewood, et al.
Molecular and Cellular Biology
|
June 21, 2001
Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium
I Rajantie, N Ekman, K Iljin, et al.
Oncogene
|
June 1, 1994
The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins
M G Borrello, G Pelicci, E Arighi, et al.
Molecular and Cellular Biology
|
January 1, 1993
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A
I Bongarzone, N Monzini, M G Borrello, et al.
Nature Genetics
|
May 1, 1995
Loss of function effect of RET mutations causing Hirschsprung disease
B Pasini, M G Borrello, A Greco, et al.
Oncogene
|
December 7, 1995
RET activation by germline MEN2A and MEN2B mutations
M G Borrello, D P Smith, B Pasini, et al.
Oncogene
|
June 29, 2001
Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein
E Mercalli, S Ghizzoni, E Arighi, et al.
Oncogene
|
February 20, 1997
Identification of Shc docking site on Ret tyrosine kinase
E Arighi, L Alberti, F Torriti, et al.
Page
of 2